MedTrace Logo

ILF With/Without Cisplatin for Advanced Gastric Cancer

NCT00320294 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2007-03-12

No results posted yet for this study

Summary

To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.

Conditions

  • Stomach Neoplasm

Interventions

DRUG

irinotecan

DRUG

cisplatin

Sponsors & Collaborators

  • Gachon University Gil Medical Center

    lead OTHER

Principal Investigators

  • Se Hoon Park, MD · Gachon University Gil Medical Center, Incheon, Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2007-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320294 on ClinicalTrials.gov